May 2, 2025 06:20 AM EDTUpdated 08:00 AM
Pharma
FDA+

Miss­ing REMS de­lays Cy­to­ki­net­ic­s' heart drug PDU­FA, stock drops

Elizabeth Cairns

Senior biopharma journalist

Cy­to­ki­net­ics said late Thurs­day that the PDU­FA date for its heart dis­ease ther­a­py afi­camten would be de­layed by three months to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

FDA ad­comm votes unan­i­mous­ly against Pfiz­er's prostate can­cer drug com­bo

Post-Hoc: AI bio needs to heed the over­hyped his­to­ry of CRISPR

Sanofi makes $470M move for Vig­il's Alzheimer's drug, while an­oth­er as­set re­turns to Am­gen

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times